Kiadis Pharma’s allodepleted T-cell immunotherapy product candidate, given after a HSCT, is designed to reduce GVHD and relapse. Single dose Phase 2 data with lead product candidate ATIR101 has demonstrated substantial and clinically relevant improvements over historical observational cohort data for a similar HSCT without ATIR101. Kiadis Pharma is conducting a Phase 3 trial (NCT02999854) with ATIR101 across Europe and North America (head to head against the PTCy/Baltimore protocol).